Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® (binimetinib), and cetuximab (BRAFTOVI Triplet) with patients suffering from advanced BRAFV600E-mutant metastatic colorectal cancer.
Reportedly, Pfizer is currently preparing to spin out its joint venture with GlaxoSmithKline Plc via IPO in the next three to four years, as informed by Albert Bourla, Pfizer CEO at the J.P. Morgan Healthcare Conference in San Francisco, last week. The association with annual sales of about $13B, will bring under one roof Advil painkillers, Tums stomach tablets, Sensodyne toothpaste, and Nicorette gum. The consumer-health joint venture with Glaxo having the majority share and Pfizer, with about a third of the business, is planning to focus on drug development. Recently, big pharma companies have shifted their focus on developing high-priced new medicines demanding research in genetics and other fields.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive!